JAMA Otolaryngol Head Neck Surg:健康医疗花费和利用率与未治疗听力损失相关性趋势研究

2018-11-29 AlexYang MedSci原创

在美国大概有3800万具有未经治疗听力损失的个体,并且与认知和功能减退相关。解决上述听力损失问题的国家方案也正在实施。最近,有研究人员基于数据库确定了是否未经治疗的听力损失与健康医疗花费的增加和利用率相关。研究人员发现,在4728名匹配的成年人中(平均基线年龄,61岁;2280名女性和2448名男性),未经治疗的听力损失患者与不患有听力损失的对照相比,10年期间的花费为22434美元(95% CI

在美国大概有3800万具有未经治疗听力损失的个体,并且与认知和功能减退相关。解决上述听力损失问题的国家方案也正在实施。最近,有研究人员基于数据库确定了是否未经治疗的听力损失与健康医疗花费的增加和利用率相关。

研究人员发现,在4728名匹配的成年人中(平均基线年龄,61岁;2280名女性和2448名男性),未经治疗的听力损失患者与不患有听力损失的对照相比,10年期间的花费为22434美元(95% CI, $18219-$26648)或者总的健康医疗花费要高出46%。那些未治疗听力损失的个人要经历更多的住院时间(发生率比。1.47;95% CI, 1.29-1.68),并且30天再住院的风险更大(相对风险,1.44; 95% CI, 1.14-1.81)。另外,研究人员在研究的2年和5年时间点观察到了相似的趋势。

最后,研究人员指出,与不患有听力损失成年人相比,年龄较大的未治疗听力损失患者需要更高的医疗花费,并且利用率更高。研究人员还指出需要进一步的研究来确定上述相关性。

原始出处:

Reed NS, Altan A, Deal JA et al. Trends in Health Care Costs and Utilization Associated With Untreated Hearing Loss Over 10 Years. JAMA Otolaryngol Head Neck Surg. 8 Nov 2018.

本文系williamhill asia 医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1677619, encodeId=59db16e76198f, content=<a href='/topic/show?id=51162e76305' target=_blank style='color:#2F92EE;'>#健康医疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27763, encryptionId=51162e76305, topicName=健康医疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Wed Jan 30 21:40:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044083, encodeId=c9092044083be, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Sep 18 16:40:00 CST 2019, time=2019-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837609, encodeId=b950183e60975, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Thu Oct 31 23:40:00 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1306294, encodeId=cd1b130629411, content=<a href='/topic/show?id=aeb639230b7' target=_blank style='color:#2F92EE;'>#听力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39230, encryptionId=aeb639230b7, topicName=听力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Sat Dec 01 03:40:00 CST 2018, time=2018-12-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1677619, encodeId=59db16e76198f, content=<a href='/topic/show?id=51162e76305' target=_blank style='color:#2F92EE;'>#健康医疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27763, encryptionId=51162e76305, topicName=健康医疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Wed Jan 30 21:40:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044083, encodeId=c9092044083be, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Sep 18 16:40:00 CST 2019, time=2019-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837609, encodeId=b950183e60975, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Thu Oct 31 23:40:00 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1306294, encodeId=cd1b130629411, content=<a href='/topic/show?id=aeb639230b7' target=_blank style='color:#2F92EE;'>#听力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39230, encryptionId=aeb639230b7, topicName=听力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Sat Dec 01 03:40:00 CST 2018, time=2018-12-01, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1677619, encodeId=59db16e76198f, content=<a href='/topic/show?id=51162e76305' target=_blank style='color:#2F92EE;'>#健康医疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27763, encryptionId=51162e76305, topicName=健康医疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Wed Jan 30 21:40:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044083, encodeId=c9092044083be, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Sep 18 16:40:00 CST 2019, time=2019-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837609, encodeId=b950183e60975, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Thu Oct 31 23:40:00 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1306294, encodeId=cd1b130629411, content=<a href='/topic/show?id=aeb639230b7' target=_blank style='color:#2F92EE;'>#听力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39230, encryptionId=aeb639230b7, topicName=听力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Sat Dec 01 03:40:00 CST 2018, time=2018-12-01, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1677619, encodeId=59db16e76198f, content=<a href='/topic/show?id=51162e76305' target=_blank style='color:#2F92EE;'>#健康医疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27763, encryptionId=51162e76305, topicName=健康医疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Wed Jan 30 21:40:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044083, encodeId=c9092044083be, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Sep 18 16:40:00 CST 2019, time=2019-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837609, encodeId=b950183e60975, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Thu Oct 31 23:40:00 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1306294, encodeId=cd1b130629411, content=<a href='/topic/show?id=aeb639230b7' target=_blank style='color:#2F92EE;'>#听力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39230, encryptionId=aeb639230b7, topicName=听力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Sat Dec 01 03:40:00 CST 2018, time=2018-12-01, status=1, ipAttribution=)]
    2018-12-01 ysjykql

相关威廉亚洲官网

盘点:听力损失研究

听力损失(hearing loss)又称聋度(deafness)或听力级(hearing level)。是人耳在某一频率的听阈比正常听阈高出的分贝数。由于年龄关系产生的听力损失称为老年性耳聋;由于社会环境噪声(年龄、职业性噪声和疾病等影响除外)产生的听力损失称为社会性耳聋;职业性噪声导致的听力损失称为噪声性耳聋。williamhill asia 医学小编整理了近期听力损失的研究进展,与大家一起分享学习!【1】HNO:听力损

盘点:听力损失相关机制研究

【1】Med Princ Pract:突发感官听力损失患者中,中性粒细胞与淋巴细胞和血小板与淋巴细胞比例研究突发性感官听力损失(SNHL)是一种常见的急性疾病,发生率在0.5-2/10000之间。最近,有研究人员确定了是否中性粒细胞与淋巴细胞比例(NLR)和血小板与淋巴细胞比例(PLR)可以作为突发性感官听力损失(SNHL)的一种预测因子。研究包括了60名SNHL确诊患者和60名健康的志愿者。

Audiol Res:具有轻度耳鸣的正常听力年轻成年人研究

中枢抑制的减少很可能与听力损失相关,并且有可能导致长期耳鸣。然而,许多具有正常听力阈值的个体报道具有耳鸣,表明了在这个群体中的感知可能来自于外围神经阻滞以外的其他来源。其中的一种测量方法就是感觉门控。感觉门控参与了非新颖输入的抑制,并且可以通过皮层听觉诱发电位(CAEP)对成对刺激的响应来测量。在典型的门控功能中,与第一次CAEP响应相比,第二次CAEP响应能够观察到明显的振幅抑制,表现出了抑制活

Sci Rep:全外显子组测序鉴定了非综合症听力损失患者KCNQ4中2个新的变异

钾离子电压门控通道亚族Q成员4(KCNQ4)变异病因上与非综合征听力损失(耳聋非综合征常染色体显性2(DFNA2))有关。最近,有研究人员对98个患有听力损失的家庭进行了全外显子组测序。研究发现,在5个家庭中发现了KCNQ4变异,并鉴定了KCNQ4中的2个先的变异:一个错义变异(c.796G>T; p.Asp266Tyr)和一个结构缺失变异(c.259_267del; p.Val87_Asn

Health Technol Assess:中耳炎伴随积液听力损失儿童的口服类固醇治疗

中耳炎伴随积液(OME)听力损失儿童一般是通过外科手术干预、听力助听器或者等待观察进行治疗。一种安全的、廉价的和有效的治疗方法能够增加治疗选择。小规模的简单试验发现口服类固醇能够产生短期的治疗效果。最近,有研究人员在患有永久OME症状和双边OME以及听力损失儿童中,确定了为期7天口服类固醇在5周内改善听力的临床效果和花费情况。研究总共包括了389名随机的儿童。在口服类固醇组和安慰剂对照组中,5周内

J Deaf Stud Deaf Educ:听力损失儿童的耳蜗移植和社会情况功能分析

最近,有研究人员调查了耳蜗移植(CIs)对耳聋或者具有听力困难(ddh)儿童的社会情绪功能的作用。研究包括了63名儿童患者,他们均为dhh。其中30名儿童为耳蜗移植使用者,32名为听力助听器(HAs)使用者。研究人员完成了优势与困难调查问卷和背景调查问卷。与那些听力助听器使用者相比,具有耳蜗移植儿童的父母报道了更低的活动过度和注意力不集中水平,以及更高的亲社会行为。另外,检测到听力损失时年龄越大,